KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gsk (GSK) EBT Margin (2016 - 2025)

Historic EBT Margin for Gsk (GSK) over the last 17 years, with Q3 2025 value amounting to 28.74%.

  • Gsk's EBT Margin rose 279400.0% to 28.74% in Q3 2025 from the same period last year, while for Sep 2025 it was 23.71%, marking a year-over-year increase of 56700.0%. This contributed to the annual value of 11.08% for FY2024, which is 89100.0% down from last year.
  • Per Gsk's latest filing, its EBT Margin stood at 28.74% for Q3 2025, which was up 279400.0% from 23.63% recorded in Q2 2025.
  • In the past 5 years, Gsk's EBT Margin ranged from a high of 29.12% in Q1 2022 and a low of 0.8% during Q3 2024
  • Moreover, its 5-year median value for EBT Margin was 20.06% (2021), whereas its average is 19.77%.
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by -211800bps in 2024, then surged by 279400bps in 2025.
  • Quarter analysis of 5 years shows Gsk's EBT Margin stood at 1.23% in 2021, then skyrocketed by 1626bps to 21.18% in 2022, then soared by 30bps to 27.56% in 2023, then crashed by -32bps to 18.69% in 2024, then surged by 54bps to 28.74% in 2025.
  • Its last three reported values are 28.74% in Q3 2025, 23.63% for Q2 2025, and 28.05% during Q1 2025.